Sponsors (20)
Introduced March 18, 2025 by Nicole Malliotakis · Last progress March 18, 2025
The bill improves U.S. medical‑supply resilience, regulatory cooperation, and enforcement for trusted partners — but does so at the risk of higher health‑care procurement costs, potential trade frictions, shifts in trade authority, and new privacy/regulatory tradeoffs.
Patients and hospitals will get more reliable access to medicines and medical devices during emergencies because the bill diversifies suppliers, expands trusted/nearby manufacturing, and expedites cross‑border movement and authorizations.
U.S. manufacturers, workers, and small exporters could gain jobs and business as the law encourages nearer‑shoring, trusted trade partnerships, regulatory cooperation, and expanded procurement access.
Taxpayers and the nation gain security benefits because reducing dependence on a few foreign suppliers lowers vulnerability to export restrictions or geopolitical disruptions.
Hospitals, patients, and consumers could face higher prices because prioritizing 'trusted' or nearer suppliers and stronger IP protections may raise procurement and drug costs.
Taxpayers may bear increased budgetary pressures because lowering or eliminating duties and supporting reshoring could reduce tariff revenue and require subsidies or other spending.
U.S. businesses and consumers risk trade tensions and retaliation if the U.S. favors certain partners or reshoring, which could disrupt trade, raise costs, and hurt exporters.
Based on analysis of 7 sections of legislative text.
Authorizes the President to negotiate 'trusted trade partner' agreements to reduce duties and barriers on medical goods, with set criteria, congressional review, and monitoring.
Creates a framework for the President and the U.S. Trade Representative to negotiate bilateral or plurilateral “trusted trade partner” agreements that remove or modify import duties and other trade barriers on medical goods to strengthen U.S. medical supply chain resilience. The bill sets criteria for eligible partners, requires advance notice and periodic reports to Congress, establishes a multi-step congressional review and disapproval process before agreements take effect, and directs ongoing monitoring and corrective options if partners fail to meet commitments.